Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Clinically relevant drug-drug interactions between antiretrovirals and antifungals.

Vadlapatla RK, Patel M, Paturi DK, Pal D, Mitra AK.

Expert Opin Drug Metab Toxicol. 2014 Apr;10(4):561-80. doi: 10.1517/17425255.2014.883379. Review.

2.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
3.

Antifungal use in HIV infection.

Marty F, Mylonakis E.

Expert Opin Pharmacother. 2002 Feb;3(2):91-102. Review.

PMID:
11829723
4.

Drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine in an HIV-infected patient treated for Aspergillus candidus lung abscess.

Becker A, Sifaoui F, Gagneux M, Desprez S, Vignoli P, Huguet D, Froidure M, Leduc D, Legout L.

Int J STD AIDS. 2015 Aug;26(9):672-5. doi: 10.1177/0956462414549035.

PMID:
25179636
5.

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.

Kumar P, DeJesus E, Huhn G, Sloan L, Small CB, Edelstein H, Felizarta F, Hao R, Ross L, Stancil B, Pappa K, Ha B; SUPPORT Study Team..

BMC Infect Dis. 2013 Jun 7;13:269. doi: 10.1186/1471-2334-13-269.

6.

Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.

Crommentuyn KM, Mulder JW, Sparidans RW, Huitema AD, Schellens JH, Beijnen JH.

Clin Infect Dis. 2004 Apr 15;38(8):e73-5.

PMID:
15095234
7.

New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.

Fera MT, La Camera E, De Sarro A.

Expert Rev Anti Infect Ther. 2009 Oct;7(8):981-98. doi: 10.1586/eri.09.67. Review.

PMID:
19803707
8.

Posaconazole: an extended-spectrum triazole antifungal agent.

Schiller DS, Fung HB.

Clin Ther. 2007 Sep;29(9):1862-86. Review.

PMID:
18035188
9.

Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.

Ofotokun I, Acosta EP, Lennox JL, Pan Y, Easley KA.

Pharmacotherapy. 2008 Jan;28(1):74-81.

10.

Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy.

Shuter J, Sarlo JA, Rode RA, Zingman BS.

HIV Clin Trials. 2009 May-Jun;10(3):135-42. doi: 10.1310/hct1003-135.

PMID:
19632952
11.

Antifungal agents in neonates: issues and recommendations.

Almirante B, Rodríguez D.

Paediatr Drugs. 2007;9(5):311-21. Review.

PMID:
17927303
12.

Modern antifungal therapy for neutropenic fever.

Corey M.

Curr Hematol Malig Rep. 2006 Jun;1(2):95-100. doi: 10.1007/s11899-006-0029-0. Review.

PMID:
20425338
13.

[New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].

van 't Wout JW, Kuijper EJ, Verweij PE, Kullberg BJ.

Ned Tijdschr Geneeskd. 2004 Aug 21;148(34):1679-84. Review. Dutch.

PMID:
15453120
14.

An update and review of antiretroviral therapy.

Piacenti FJ.

Pharmacotherapy. 2006 Aug;26(8):1111-33. Review.

PMID:
16863488
15.

New antifungal agents.

Gupta AK, Tomas E.

Dermatol Clin. 2003 Jul;21(3):565-76. Review.

PMID:
12956208
16.

Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.

Kasserra C, O'Mara E.

Clin Pharmacokinet. 2011 Apr;50(4):267-80. doi: 10.2165/11584560-000000000-00000.

PMID:
21348539
17.

Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.

Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK.

Cochrane Database Syst Rev. 2014 Feb 24;(2):CD004707. doi: 10.1002/14651858.CD004707.pub3. Review.

PMID:
24563222
18.
19.

Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.

Wire MB, Shelton MJ, Studenberg S.

Clin Pharmacokinet. 2006;45(2):137-68. Review.

PMID:
16485915
20.

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.

Eron J Jr, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, Lackey P, Katlama C, Young B, Yau L, Sutherland-Phillips D, Wannamaker P, Vavro C, Patel L, Yeo J, Shaefer M; KLEAN study team..

Lancet. 2006 Aug 5;368(9534):476-82. Erratum in: Lancet. 2006 Oct 7;368(9543):1238.

PMID:
16890834

Supplemental Content

Support Center